Impact of multivessel percutaneous coronary intervention vs. culprit vessel percutaneous coronary intervention in patients with acute coronary syndromes and multivessel coronary artery disease

• Published in: Cardiovascular revascularization medicine 2023-08, Vol.53, p.38-44
• Main Authors: Yasuda, Kentaro, Ogita, Manabu, Tsuboi, Shuta, Nishio, Ryota, Takeuchi, Mitsuhiro, Sonoda, Taketo, Wada, Hideki, Suwa, Satoru, Miyauchi, Katsumi, Daida, Hiroyuki, Minamino, Tohru
• Format: Article
• Language: English
• Subjects: Acute coronary syndrome; Long-term outcomes; Multivessel coronary artery disease; Multivessel PCI; Percutaneous coronary intervention
• ISSN: 1553-8389; 1878-0938
• DOI: 10.1016/j.carrev.2023.02.024

Recent clinical trials have shown that percutaneous coronary intervention (PCI) for non-culprit lesions (NCLs) reduces the risk of adverse events in patients with ST-segment elevation myocardial infarction (STEMI), but the effect on long-term outcomes remains unclear in acute coronary syndrome (ACS) patients and a real-world clinical setting. A retrospective observational cohort study of ACS patients who underwent primary PCI between April 2004 and December 2017 at Juntendo University Shizuoka Hospital, Japan, was performed. The primary endpoint was the composite of cardiovascular disease death (CVD death) and non-fatal myocardial infarction (MI) during the mean follow-up period of 2.7 years, and a landmark analysis for the incidence of the primary endpoint from 31 days to 5 years between the multivessel PCI group and the culprit only PCI group was performed. Multivessel PCI was defined as PCI including non-infarct-related coronary arteries within 30 days after the onset of ACS. Of the 1109 ACS patients with multivessel coronary artery disease of the current cohort, multivessel PCI was performed in 364 (33.2 %) patients. The incidence of the primary endpoint from 31 days to 5 years was significantly lower in the multivessel PCI group (4.0 % vs. 9.6 %, log-rank p = 0.0008). Multivariate Cox regression analysis showed that multivessel PCI was significantly associated with fewer cardiovascular events (HR 0.37, 95 % CI 0.19–0.67, p = 0.0008). In ACS patients with multivessel coronary artery disease, multivessel PCI may reduce the risk of CVD death and non-fatal MI compared to culprit-lesion-only PCI. [Display omitted] •Half of ACS patients had multivessel CAD.•Multivessel PCI was performed in one-third of ACS patients.•Incidence of CVD death and non-fatal MI from 31 days to 5 years was significantly.•Lower in multivessel PCI group (adjusted HR 0.37, 95%CI 0.19–0.67, p value = 0.0008)